ClinicalTrials.gg
CompletedNCT04649593GBUpdated Mar 31, 2022

The Study of Giving Birth, a Study About Treatment of Labor Dystocia

An interventional study of Samarin in Dystocia, sponsored by Karolinska Institutet. Completed at 1 site in Sweden. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-03-31.

Sponsored by Karolinska Institutet · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 10 months after the study started (first participant enrolled Jan 2020, registered Nov 2020).
Phase
Not applicable
Study type
Interventional
Enrollment
2,000
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Study summary

Labor dystocia is an intransigent, high-profile issue in obstetric care, which causes significant maternal morbidity in low resource settings and maternal dissatisfaction, and increased healthcare costs worldwide. Amniotic fluid lactate, (AFL), values have recently been shown to reflect the metabolic status of the uterus and high levels have a strong association with subsequent need for operative intervention due to dystocia. In sports medicine, it is known that lactic acid can affect muscular performance but be decreased by bicarbonate given orally before physical activity. Main Outcome Measures: If an intake of bicarbonate, one hour before stimulation with oxytocin in cases with a high AFL value, changes the AFL levels and enhances delivery outcome in dystocic deliveries.

Design: Randomized controlled trial

Read the detailed description

Primary question: whether high AFL values (>12mmol/l) in women with observed dystocic labor are best treated by

  1. to handle childbirth according to the clinic's current guidelines in case of labor dystocia, i.e. with oxytocin stimulation
  2. an intake of bicarbonate (Samarin) dissolved in water given 1 hour before the oxytocin is started Primary outcome variable A comparison of the frequency of spontaneous vaginal delivery in the observed two described intervention groups.
02

Conditions studied

  • Dystocia

Browse trials for

03

In context

Dystocia

55 studies on the registry are indexed under Dystocia; 12 are open to participants now.

This study's enrollment of 2,000 is above the median of 200 across 42 interventional studies indexed under Dystocia.

Browse Dystocia studies →

Lead sponsor

Karolinska Institutet is the lead sponsor of 1,148 studies on the registry; 276 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • dystocic labor with a need of oxytocin >=34w of gestation

Exclusion criteria

Exclusion Criteria:

  • Nondystocic labors.
  • Women who don't understand Swedish or English
  • Premature deliveries (\<34w)
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
2,000 participants (actual)

Study arms

  • No intervention
    according to clinical guidlines

    Dystocic progress and an observed low AFL value (\< 12.0 mmol/l).

  • Experimental
    intevention

    At dystocic labor and an observed high AFL value, the woman is randomized to one of the intended two study groups. Group 1) Delivery according to the clinic's guidelines in case labor dystocia, i.e., oxytocin stimulation Group 2) Two bags of Samarin mixed in a glass of water. After an hour, In case of lack of progress, oxytocin stimulation is started.

    Dietary Supplement: Samarin

Interventions

  • Dietary supplementSamarin

    Half of the group with a high AFL value will have a glass of Samarin to drink

06

What researchers measure

Primary outcomes

  1. Labor outcome

    Labor outcome in the different groups (spontaneous vaginal, VE or caesarean section)

    Time frame: through study completion, an average of 1 year

  2. AFL values

    AFL-values to be at different times during labor

    Time frame: through study completion, an average of 1 year

Secondary outcomes

  1. The use of oxytocin

    Oxytocin stimulation (number of hours of stimulation and amount of oxytocin given),

    Time frame: through study completion, an average of 1 year

07

Study locations

1 site
  • Eva Wiberg-Itzel
    Stockholm, 18239, Sweden
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2020 to primary completion in Dec 2021, 23 months.

Of 18 interventional studies with no phase under Dystocia, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 40. This study's 23 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 22, 2020
First posted
Dec 2, 2020
StartActual
Jan 1, 2020
Primary completionActual
Dec 30, 2021
CompletionActual
Feb 28, 2022
Last update
Mar 31, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 31, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04649593
Responsible party
Eva Wiberg-Itzel (Associate professor, Karolinska Institutet) — Principal investigator
First posted
Dec 2, 2020
Start date
Jan 1, 2020
Primary completion
Dec 30, 2021
Completion
Feb 28, 2022
Last update
Mar 31, 2022

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion